Kiin Bio: AI-Powered Drug Discovery Platform
Kiin Bio is one of seven winners of the second ELSA Industry Call and has received 60,000 euros in funding. For the duration of the Industry Call, Kiin Bio has worked together with top AI experts within our Network of Excellence. Kiin Bio develops an AI-native platform that unifies drug discovery tools.
Result Video
In this video, the team presents the joint project with ELSA:
Short Summary
Kiin Bio’s short summary of the project:
The discovery of new therapeutics remains constrained by the complexity of experimental design and the high cost of exploring large biological and chemical spaces. Kiin Bio was founded to address this challenge by developing an AI platform that combines LLM-based reasoning, structured experimental knowledge, and computational biology tools to automate and augment scientific planning.
Support from the ELSA Industry Call 2 enabled Kiin Bio to accelerate the technical and scientific development of this platform. The project focused on six interconnected workstreams designed to improve scalability, reasoning quality, tooling breadth, data benchmarking, community engagement, and fundraising.”
Learn more about KiinBio on their website.